# A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

> **NCT01614522** · PHASE2 · COMPLETED · sponsor: **ASLAN Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Stomach Neoplasms
- Cancer of Stomach
- Cancer of the Stomach
- Gastric Cancer
- Gastric Neoplasms

## Interventions

- **DRUG:** ASLAN001

## Key facts

- **NCT ID:** NCT01614522
- **Lead sponsor:** ASLAN Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01614522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01614522, "A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01614522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*